A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Corcept treats a rare hormonal disorder and is trying to apply the same mechanism in oncology.
The lead drug blocks the action of cortisol in a syndrome where the body produces it in excess. The condition is rare, diagnosed late, and treatments were few — the company took that niche and remains profitable, which is unusual for a small pharmaceutical company.
What follows depends on two things: a next-generation drug without the first one's side effects, and applying the same mechanism in ovarian cancer, where early data are encouraging. A constant background is litigation with generic manufacturers, since the active substance has long been known. Risks: patent protection, trial outcomes and the narrowness of the current market. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Corcept Therapeutics Incorporated (CORT) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Corcept Therapeutics Incorporated (CORT) on November 17, 2026 is $69.85, +0.91% on the day. Over 52 weeks the stock traded between $28.66 and $126.38; the price now sits 42% of the way up that range. Over the past year the price changed by −7.53%. The P/E ratio is 134.13, which is above the sector median (25.67). Market capitalisation is $7.40 billion, rank 31 among 381 stocks of the same industry with a known capitalisation.
Corcept Therapeutics Incorporated trades on Nasdaq under the ticker CORT. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks CORT has traded between $28.66 and $126.38. As of 17 November 2026 the price stood 42.15% of the way from the 52-week low to the high.
Over one year CORT shares fell 7.53%; over six months they rose 26.72%. Volatility over 90 days is 71.95%. Dividends are not included: this is price change only, as of 17 November 2026.
CORT trades at a price-to-earnings ratio of 134, above the sector median of 25.7. Price to sales is 8.9, above the sector median of 3.5. Price to book is 10.5, above the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
Corcept Therapeutics Incorporated reported revenue of $831M and net income of $55M over the last four quarters. Net margin is 6.64%. Revenue changed by +16.02% year over year. Earnings per share are $0.45. Market capitalisation is $7.4B.
CORT has a return on equity of 7.82%, above the sector median of −40.58%. Return on assets is 6.21%, above the sector median of −30.08%. Operating margin is 0.77%, above the sector median of −20.96%.